Elephas is a biotech company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development.
Elephas is leading the way to change how clinicians treat cancer patients.
Elephas was founded in 2020 by Maneesh Arora. The company is headquartered in Madison, Wisconsin.
Elephas utilizes live fragments from a patient biopsy and treats those fragments with potential therapies and combinations. The latest advances in cancer biology, multimodal microscopy, and artificial intelligence, to empower clinical decision making and accelerate drug development.
Elephas maintains the native 3-dimensional cellular architecture of a patient’s tumor and enable ex-vivo real-time profiling of live tumor samples. The platform is being developed for use with immunotherapy agents alone and in combination with traditional chemotherapy and targeted therapies.
Elephas is launching two human clinical trials on the platform in the next quarter and plans to share initial clinical data in 2023. The company also plans to make the platform available to biopharma researchers next year.
Elephas is backed by ARCH Venture Partners, Moore Strategic Ventures, Northpond Ventures, Sands Capital, Tao Capital Partners, WARF Ventures, and others. The company raised $41.5M in Series B round on Sep 06, 2022. This brings Elephas' total funding to $68.5M to date.